Watson Settles With Teva Women’s Health, Launches Generic Version of LoSeasonique

Watson Pharmaceuticals Inc. Dec. 7 announced it has launched a generic version of Teva Women’s Health’s branded contraceptive LoSeasonique after reaching a patent litigation settlement with Teva Women’s Health (Teva Women’s Health Inc. v. Lupin Ltd.).

U.S. District Judge Claire C. Cecchi of the U.S. District Court for the District of New Jersey Dec. 9 dismissed the patent litigation with prejudice, pursuant to a stipulation signed by the parties.

Terms of the settlement were not disclosed.

As a first applicant to submit a substantially complete abbreviated new drug application for the product, Watson is eligible for 180 days ...